Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Ontology highlight
ABSTRACT: The histone H3 lysine 4-specific methyltransferase SETD1A is associated with transcription activation and is considered a key epigenetic regulator that modulates the cell cycle and metastasis in triple-negative breast cancer cells. However, the clinical role of SETD1A in estrogen receptor (ER)-positive breast cancer cells remains unclear. Here, we examined whether SETD1A is a potential target for ER?-positive breast cancer therapy. SETD1A expression was upregulated in breast tumor tissue compared to that in normal breast tissue. Moreover, ER-target genes regulated by SETD1A were particularly enriched in cell cycle and cancer pathways. SETD1A is involved in histone H3K4 methylation, subsequent recruitment of ER?, and the establishment of accessible chromatin structure at the enhancer region of ER? target genes. In addition to ER? target genes, other cell survival genes were also downregulated by SETD1A depletion in MCF-7 cells, leading to significant decrease in cell proliferation and migration, and spontaneous induction of apoptosis. We also found that miR-1915-3p functioned as a novel regulator of SETD1A expression in breast cells. Importantly, the growth of tamoxifen-resistant MCF-7 cells was effectively repressed by SETD1A knockdown. These results indicate that SETD1A may serve as a molecular target and prognostic indicator in ER?-positive breast cancer.
SUBMITTER: Jin ML
PROVIDER: S-EPMC6278950 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA